Insmed will discontinue a program evaluating brensocatib to treat a chronic inflammatory skin condition after a Phase 2b study failed to meet its primary or secondary endpoints. The biopharmaceutical ...

Insmed's updated fair value estimate has shifted slightly, from US$214.32 to US$212.50 per share, putting fresh attention on how analysts are recalibrating their views. Recent reports around Brinsupri ...

CEO Will Lewis highlighted the strong start to 2025, driven by double-digit year-over-year revenue growth for ARIKAYCE and progress in mid to late-stage clinical programs. The FDA's review of the NDA ...

Insmed INSM announced that it is discontinuing the development of Brinsupri (brensocatib) for hidradenitis suppurativa (HS) ...

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in ...

Lewis said, "The next 12 months for Insmed are shaping up to be extraordinarily impactful," with expectations of up to 10 additional commercial, clinical development, and regulatory milestones. The ...

Insmed Incorporated (NASDAQ:INSM) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company eyes Brensocatib approval by August 12, and its TPIP Phase 3 and $750 million funding bolsters ...

"The PANTHERx team is pleased to be chosen by Insmed to dispense BRINSUPRI™, the first and only FDA-approved treatment for NCFB," said Bansi Nagji, CEO, PANTHERx® Rare Pharmacy. PANTHERx Rare is a ...